TELA Bio receives FDA 510(k) clearance for OviTex PRS Long-Term Resorbable

TELA Bio, Inc.

FDA granted 510(k) clearance on March 23, 2023 for OviTex PRS Long-Term Resorbable.
Product reinforces soft tissue in plastic and reconstructive surgery where weakness exists.
Complements existing OviTex PRS Permanent and Short-Term Resorbable configurations.
Design features bi-directional stretch and a fully resorbable long-term polymer.
CEO Antony Koblish states it expands clinical utility and demonstrates tunable design capabilities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.